Neoantigen Personalized Cancer Vaccine
Phase 1Vaccine
Neoantigen Personalized Cancer Vaccine is one of 7 biologic programs targeting Gastrointestinal. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gastrointestinal
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Phase 3
Cytalux
OOn Target Laboratories, LLC
Phase 3
Octreotide
Johnson & JohnsonPreclinical
Neoantigen Personalized Cancer Vaccine
RRuijin Hospital
Phase 1
Mosapride Citrate
IlDong Pharmaceutical Co LtdPreclinical
Buscopan
Boehringer IngelheimPreclinical
Dachengqi Decoction
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company
- RRuijin Hospital